Listed as stock code 6969.HK, its initial IPO price was 12.4HKD, while the closing price reached 31 HKD and market value 178 billion HKD. Smoore is a global leader in offering vaping technology solutions and its mission is building the world’s leading vaping technology platform, with innovation and the vaping technologies with a wide range of applications in mind.
“Smoore is a global leader in manufacturing vaping devices and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. According to Frost & Sullivan, Smoore was the world’s largest vaping device manufacturer in terms of revenue, accounting for 16.5% of the total market share, in 2019,” said a release by Smoore.
Smoore’s has witnessed a compound annual growth rate of 120.8%
Data has indicated that between 2016 and 2019, the company’s total revenues were 707 million yuan, 1.565 billion yuan, 3.434 billion yuan, and 7.611 billion yuan respectively, with a compound annual growth rate of 120.8%. The majority of Smoore’s customers come from overseas markets, covering more than 50 overseas countries or regions. In 2019, the company’s revenue from the United States, Hong Kong and Japan markets, accounted for 21.8%, 20.9% and 7.9%, respectively.
Vaporesso owned by SMOORE since 2015
Renowned brand Vaporesso, has inherited SMOORE’s culture and incorporated it into its own mission to be Beyond the Ordinary. “With cutting-edge ingenuity, VAPORESSO is dedicated to satisfying its customers with the high-quality vaping experience. VAPORESSO’s products – such as VECO, ZERO, LUXE and the GEN family – cover the full range of open-system vapes and fulfil the various needs from the vapers.”
Since joining SMOORE in 2015, VAPORESSO’s business has spread to over 60 countries and regions around the world and has established a substantial brand influence in Europe, America, and emerging markets.
By working closely together with partners, and maintaining consistent innovation and craftsmanship, VAPORESSO aims to keep providing high-quality products and services for its existing 800 million happy users, whilst contributing to a better future for the vaping industry.
IF Design Award 2020
Earlier this year, FEELM, an atomization brand and an independent business unit of Smoore won the IF Design Award 2020 for its eco-friendly Disposable Paper E-cigarette. This award is presented on a yearly basis to winners of a world-renowned design competition, which was first launched in 1953. Products entered in the competition are assessed on criteria such as packaging, architecture, service design, etc.
The FEELM Ceramic Coil Atomization Technology
FEELM is also renowned for it’s Ceramic Coil and the Atomization technology it comes with. Atomization is a process that is very common in daily life, and is carried out by devices such as humidifiers, facial steamers, fog machines, and so on. Atomization techniques vary widely, yet at the core of the process is the coil. Nowadays, coil materials vary widely and include glass fiber, organic cotton and metallic mesh, yet ceramic has developed to be an essential part of high quality coils.
The FEELM coils are composed of a ceramic substrate and a layer of metallic film. The ceramic is sintered at a high temperature and formed into the shape of a bowl. The metallic film is printed onto the substrate surface with an “s-shape” in order to provide efficient and even heating, just like a stove and pot in cooking. The atomizer vapourizes the e-liquid into vapour as it is heated by the metallic film at the precise temperature.
When compared to other materials such as fiber and cotton, the FEELM coil’s physical structure, material property and industrial design, contribute to a faster rise in temperature and even temperature distribution on the substrate surface. This precise temperature control enabled by the FEELM technology can greatly reduce the amount of aldehydes and ketones produced during the vaporization process.
“While providing electronic atomization products to global users, SMOORE has also begun to explore new applications of atomization technology. This April, Smoore and AIM Immuno Tech (hereinafter referred to as “AIM”) announced they have entered into a Material Transfer and Research Agreement (MTA). The purpose is to research in China the efficacy of Smoore’s inhalation delivery device using Ampligen, AIM’s flagship drug, which has been approved for ME/CFS in Argentina and experimental through phase 3 clinical trials in the U.S. AIM believes Ampligen has potential as a prophylactic/early-onset therapeutic against COVID-19. When a patient shows COVID-19 symptoms for the first time, the drug is delivered deep into the infected lung, which can cause the drug to trigger a therapeutic Toll Like Receptor 3 (TLR3) throughout the upper and lower respiratory systems, thereby effectively preventing COVID-19 infection.
Globally, inhalation therapy using electronic atomization equipment has become an important and effective method for treating respiratory symptoms and diseases (such as cough, asthma, bronchitis, and other lung diseases), and more and more electronic atomization equipment suppliers have begun to strengthen researches and investments in this area. With increasing awareness of practitioners in electronic atomization industry, medical applications may become an important part in the future.
Applying electronic atomization technology to the healthcare industry is one of the key points in Smoore’s next phase of research, and is also a potential driver for its future development.
Currently, Smoore is developing core components for medical automation equipment. With its automated production technology, Smoore can simplify the existing medical automation equipment, accurately control the dosage and the size of aerosol particle, so as to improve the atomization efficiency of health care essence.
Specifically, controlling the aerosol particle size can ensure that a higher ratio of drug aerosol enters the human body and being effectively absorbed, while controlling the dose can ensure that the patient takes the appropriate amount of medicine. In the precise calculation of medicines, SMOORE has made breakthroughs, contributing to treat asthma, chronic obstructive pulmonary disease and other respiratory diseases, and relieve pains.”
